Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Continuing to improve outcomes of men with metastatic prostate cancer.

Saad F.

Nat Rev Clin Oncol. 2019 Jul 16. doi: 10.1038/s41571-019-0254-9. [Epub ahead of print] No abstract available.

PMID:
31312041
2.

A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, Suardi N, Briganti A, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M.

Eur Urol. 2016 May;69(5):788-94. doi: 10.1016/j.eururo.2015.05.023. Epub 2015 May 30.

PMID:
26038098
3.

Management of patients with metastatic prostate cancer.

Turner B, Drudge-Coates L.

Nurs Stand. 2012 Mar 7-13;26(27):49-57; quiz 58.

PMID:
22482176
4.

Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.

Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.

Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26. Review.

5.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S.

Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.

PMID:
29752180
6.

Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.

Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS.

Cancer. 2018 May 1;124(9):1921-1928. doi: 10.1002/cncr.31285. Epub 2018 Mar 2.

7.

Cytoreductive surgery for men with metastatic prostate cancer.

Katelaris N, Murphy D, Lawrentschuk N, Katelaris A, Moon D.

Prostate Int. 2016 Sep;4(3):103-6. doi: 10.1016/j.prnil.2015.11.003. Epub 2015 Dec 12.

8.

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.

Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM.

Eur Urol Oncol. 2018 Dec 3. pii: S2588-9311(18)30203-7. doi: 10.1016/j.euo.2018.11.005. [Epub ahead of print]

9.

Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.

Kelly SP, Anderson WF, Rosenberg PS, Cook MB.

Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.

10.

The economic burden of prostate cancer survivorship care.

Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK.

J Urol. 2010 Aug;184(2):532-8. doi: 10.1016/j.juro.2010.03.136. Epub 2010 Jun 17.

PMID:
20620413
11.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

14.

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS.

N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.

16.

Prostate cancer outcomes for men who present with symptoms at diagnosis.

Beckmann KR, O'Callaghan ME, Ruseckaite R, Kinnear N, Miller C, Evans S, Roder DM, Moretti K; South Australian Prostate Cancer Clinical Outcomes Collaborative.

BJU Int. 2017 Jun;119(6):862-871. doi: 10.1111/bju.13622. Epub 2016 Sep 3.

17.

Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.

Dalela D, Sun M, Diaz M, Karabon P, Seisen T, Trinh QD, Menon M, Abdollah F.

Eur Urol Focus. 2019 Jan;5(1):77-80. doi: 10.1016/j.euf.2017.04.012. Epub 2017 May 12.

PMID:
28753893
18.

Is it truly outrageous to consider radical prostatectomy for men with metastatic prostate cancer?

Gautam G.

Indian J Urol. 2014 Oct;30(4):366-7. doi: 10.4103/0970-1591.139593.

19.

The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.

Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):273-9. doi: 10.1038/pcan.2014.23. Epub 2014 Jul 1.

PMID:
24980272
20.

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ.

Clin Genitourin Cancer. 2013 Dec;11(4):397-406. doi: 10.1016/j.clgc.2013.05.007. Epub 2013 Jul 3.

PMID:
23830964

Supplemental Content

Support Center